Treatment News : Seroconverting on PrEP Not a Major Risk For Truvada Resistance

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » May 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


May 27, 2014

Seroconverting on PrEP Not a Major Risk For Truvada Resistance

Those taking Truvada (emtricitabine/tenofovir) as pre-exposure prophylaxis (PrEP) are not at a major risk of developing resistance to the components of the drug should they seroconvert, aidsmap reports. There is a significant risk, however, if someone is experiencing acute HIV infection when he or she begins taking PrEP. Researchers published this analysis of data from the iPrEx study in the Journal of Infectious Diseases.

The iPrEX study, which first proved PrEP’s efficacy, involved 2,451 participants who were equally randomized to receive either Truvada or a placebo. During the study, 141 participants seroconverted, including 10 people who had acute HIV infections that went undetected when they were randomized. Two of these people were in the treatment arm, both of whom developed resistance to emtricitabine.

Out of the 131 seroconversions that took place after randomization, 48 were in people in the treatment arm. None of them had resistance to the components of Truvada. Two of them did show minor variant emtricitabine-associated resistance, but both to a very low effect.

To read the aidsmap story, click here.

To read the study abstract, click here.

Search: HIV, pre-exposure prophylaxis, PrEP, Truvada, emtricitabine, tenofovir, drug resistance, aidsmap.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.